Connect with us

Health

Germany Approves Limited Use of Psilocybin Therapy for Depression in Landmark Move

Published

on

In a major breakthrough for mental health treatment in Europe, Germany’s medicine regulator has approved the use of psilocybin therapy for select patients suffering from treatment-resistant depression. The move marks the first time within the European Union that psilocybin—the psychoactive compound found in so-called “magic mushrooms”—will be made available under a compassionate use programme.

The decision, announced by the Federal Institute for Drugs and Medical Devices (BfArM), allows for the controlled use of psilocybin in “justified exceptional cases.” Only patients who have not responded to standard treatments for depression will be eligible, and therapy must be conducted under strict medical supervision.

Dr. Gerhard Gründer, head of the molecular neuroimaging department at the Central Institute of Mental Health (CIMH) in Mannheim, which submitted the request for the programme, described the development as a “milestone.” He noted that for patients facing severe depression with no effective alternatives, psilocybin therapy could be “a medically and ethically justifiable option.”

According to CIMH, between 20% and 30% of people diagnosed with depression do not respond adequately to existing medications or therapies. Recent research suggests that psilocybin may help by disrupting ingrained thought patterns and enhancing brain connectivity, offering potential relief where conventional treatments fail.

While optimism around psychedelics is growing, some researchers caution that results from early clinical trials have proven difficult to replicate. Nonetheless, momentum continues to build across Europe. Earlier this month, the Czech Republic also legalised psilocybin for medical use in specific mental health conditions.

Germany’s decision follows a broader wave of interest in psychedelic-assisted therapies for mental health issues, including anxiety, post-traumatic stress disorder (PTSD), and addiction. Clinical trials across Europe are currently exploring the efficacy of psychedelics, including a major EU-funded study investigating psilocybin’s role in treating anxiety and depression in patients with progressive neurological diseases such as multiple sclerosis (MS) and ALS.

See also  Sugar Drops Can Reduce Pain for Babies During Needle Procedures, Study Finds

Approval for widespread clinical use of psilocybin in Germany is not expected for several years. However, advocates say the compassionate use model is a critical interim step. The Psychedelic Access And Research European Alliance (PAREA), a nonprofit group promoting responsible access to these treatments, said such programmes can offer real-world insights and support patients who “cannot wait” for formal approval.

Dr. Gründer said CIMH anticipates high demand for the programme, noting that “experience from Switzerland shows that demand far exceeds the available supply.”

“We must therefore continue to work on bringing psychedelics such as psilocybin into standard care for the treatment of mental illness,” he added.

Health

More Europeans Take Up Sport, but Major Gaps Remain Across Countries

Published

on

More Europeans are exercising regularly than they were four years ago, but participation continues to vary sharply depending on where people live, their age, education and financial circumstances, according to a new European Commission survey.

The latest Eurobarometer survey on sport and physical activity found that 39% of respondents said they never exercise or play sport, down from 45% in 2022. Nearly half of the 26,508 people surveyed said they exercise or play sport every day or several times a week.

The results also showed wide differences between countries. Finland recorded the highest share of people exercising daily, at 21%, followed by Denmark at 20%. In both countries, another 59% of respondents said they exercise several times a week.

At the other end of the scale, 68% of respondents in Portugal said they never exercise or play sport. Greece and Romania followed, with 66% in each country reporting that they never take part in sport or exercise.

Time was the most commonly cited barrier among people who wanted to exercise more, with 37% identifying it as an obstacle. A lack of motivation or interest was mentioned by 26%, while 15% pointed to health problems or injury. Cost was cited by 12%.

Education and household finances were also closely linked to participation. Some 59% of people who continued their education until at least the age of 20 said they exercise or play sport several times a week. That compared with 23% among those who left education at 15 or younger.

Financial circumstances showed a similar divide. People who said they had the greatest difficulty paying their bills were twice as likely to report never exercising as those who rarely or never faced financial difficulties, at 54% compared with 26%.

See also  WHO Warns European Health Systems Are Failing Victims of Gender-Based Violence

“More Europeans are getting active, but the opportunity to take part still depends too much on income, age and education,” said Roxana Mînzatu, Executive Vice-President for Social Rights and Skills, Quality Jobs and Preparedness.

The survey also highlighted a significant age gap. Nearly three-quarters of people aged 15 to 24 exercise or play sport at least several times a week, compared with 25% of those aged 75 and over. Health problems or injury were the main barrier for older respondents, while younger and middle-aged people were more likely to cite a lack of time.

Physical activity linked to everyday life also increased. Active commuting rose from 24% in 2022 to 37%, while 72% of respondents said they now walk for at least 10 minutes at a time.

The survey found, however, that some Europeans do not consider their neighbourhoods suitable for walking or cycling, potentially restricting opportunities for active travel.

Mînzatu said affordable sport and safe places to exercise should be available close to where people live, including for children from families unable to afford club fees, older people and those with disabilities.

Continue Reading

Health

Congenital Infections Linked to Higher Risks of Autism and Intellectual Disability

Published

on

Children born with certain infections acquired during pregnancy face substantially higher risks of autism and intellectual disability later in life, according to a study of more than 3.7 million people in Sweden.

Researchers found that children with congenital infections were about three times more likely to be diagnosed with autism and more than seven times more likely to receive a diagnosis of intellectual disability than those without such infections.

The findings suggest that infections transmitted from a pregnant woman to her foetus may have lasting effects on brain development, although the study identifies an association rather than proving that the infections directly cause autism or intellectual disability.

The research focused on TORCH infections, a group that includes syphilis, rubella, toxoplasmosis, cytomegalovirus and herpesvirus. These infections can cross the placenta and affect the developing foetus, potentially increasing the risk of miscarriage, stillbirth and other pregnancy complications.

“Although these congenital infections are rare, some of them can be prevented, which makes them important from a public health perspective,” said Reneé Gardner of the Department of Global Public Health at Karolinska Institutet, who contributed to the study.

The researchers examined people born in Sweden between 1987 and 2021 and followed them for up to 30 years. Among the 3.7 million participants, 975 had been diagnosed with a congenital TORCH infection.

Although congenital infections accounted for only a small proportion of autism cases across the population, the risk among affected children was considerably higher. The researchers estimated that about one in five children born with a TORCH infection could later develop autism.

See also  Experts Warn Poorly Designed Tech Could Add to Doctors’ Workload, Not Ease It

The study also found elevated risks of intellectual disability across different levels of severity. The risk of severe to profound intellectual disability was as much as 30 times higher among children with a congenital infection than among those without one.

The researchers found evidence of an impact on educational outcomes even among people who were not diagnosed with autism or intellectual disability. A total of 420 participants with a TORCH infection showed poor school performance without receiving either diagnosis.

Congenital cytomegalovirus, or CMV, is the most common of these infections globally and affects roughly one in 150 newborns. Its burden is substantially greater in low- and middle-income countries.

The researchers said the findings highlight the importance of prevention, particularly in regions where these infections are more common. They pointed to vaccination programmes and other preventive measures as important tools for reducing congenital infections.

They also called for improved identification of affected newborns. Current screening systems, including those used in Sweden, may miss asymptomatic infections because universal screening for TORCH infections is not routinely carried out.

The authors said stronger screening and prevention strategies could help identify children at risk earlier and improve long-term support and care.

Continue Reading

Health

AI Chatbots Make Faster, Less Nuanced Kidney Transplant Decisions Than Doctors

Published

on

Artificial intelligence chatbots may make faster and more confident decisions than human doctors when determining which patient should receive a life-saving kidney transplant, but a new study found that the systems often rely on fewer factors and show less sensitivity to the ethical complexity of such choices.

Researchers from Penn State University in the United States compared decisions made by large language models (LLMs) with choices made by people in earlier studies on kidney allocation. The researchers presented AI models with hypothetical cases based on existing datasets in which human participants had previously chosen between two patients competing for a single available kidney.

The patients were described using characteristics including age, health and drinking habits. Both were considered eligible for the transplant, requiring the decision maker to determine which patient should receive the available organ.

The researchers tested the AI systems in several ways. Some scenarios focused on individual characteristics, while others combined several traits to examine how the models handled competing considerations. In some tests, participants and AI systems were also given the option of flipping a coin, allowing researchers to assess indecision as part of moral decision-making.

Human participants generally placed greater importance on age, often favouring younger patients over older patients. Many of the AI models, however, placed greater weight on lower alcohol consumption.

Hadi Hosseini, the study’s lead researcher at Penn State University, said the findings showed that AI chatbots can diverge from human values when weighing characteristics of patients.

The researchers found that human decisions tended to consider several factors together and were more sensitive to context. LLMs, by contrast, frequently focused on a single characteristic when making their choices.

See also  Switzerland Reports First Case of Contagious New Mpox Strain as Outbreak Spreads Across Europe

Another difference involved uncertainty. Human participants were more likely to recognise that organ allocation can involve competing ethical considerations and that there may not be one objectively correct answer. AI models generally showed little hesitation and committed to one choice.

John Dickerson, chief executive officer of Mozilla.ai and a collaborator on the study, said humans recognise ambiguity when allocating scarce resources and use debate to shape how such decisions are made.

The findings come as AI systems are increasingly being used in healthcare for clinical workflows, diagnosis, treatment planning and decisions involving limited medical resources.

The researchers said kidney allocation presents a particularly important test because decisions over deceased-donor and living-donor organs involve medical, ethical and moral considerations.

Hosseini said the ethical stakes are high because decisions involving organ allocation can directly affect patients’ lives. He stressed that the study was not intended to encourage replacing professional medical judgment with AI.

Instead, the researchers said understanding how AI systems behave in high-stakes situations is becoming increasingly important as individuals, organisations and businesses use AI to make decisions or provide recommendations.

Continue Reading

Trending